# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Ludger DINKELBORG et al.

Serial No.:

09/508,972

Filed:

May 24, 2000

For:

METHOD FOR TREATING PROLIFERATIVE DISEASES BY THERAPY

Group Art Unit: 3762

### REQUEST FOR CORRECTED FILING RECEIPT

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

According to the formal Filing Receipt (copy attached), please make the corrections li MAIL ROOM below:

### In the Foreign Applications Section:

Please correct the application number of the third priority document:

It should read GERMANY 197 42 <u>8</u>80.0 09/23/1997

A copy of the Declaration and Power of Attorney as filed with the application is attached which lists the correct priority number. Therefore, no fee is required herein.

Respectfully submitted

Richard J. Traverso (Reg. No.

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I 2200 Clarendon Blvd., Suite 1400

Arlington, VA 22201

Direct Dial: (703) 812-5310

Internet address: traverso@mwzb.com

Filed: June 29, 2000

AJZ\ap:K:\PAT\Sch\1737\req cor OFR.wpd

# CLIENT COPY

#### Patent and Trademark Office UNITED STATES DEPARTMENT OF COMMERCE

COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231 Address: ASSISTANT SECRETARY AND










·OC00000002162827\*

	58	3	SCH1737	<b>カカカト</b>	3762	02/54/2000	276,802/60
IND CLAIMS	TOT CLAIMS	гымаяа	ATTY.DOCKET.NO	FIL FEE REC'D	ТІИО ТЯА ЧЯЭ	EILING DATE	A38MUN NOITADIJ99A



PRLINGTON, VA 22201 SUITE 1400 SS00 CLARENDON BOULEVARD ARLINGTON COURTHOUSE PLAZA I MILLEN WHITE ZELANO & BRANIGAN

Filing Receipt incorporating the requested corrections (if appropriate). your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another "Motice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be

(e)transilgqA

FRIEDHELM BLUME, BERLIN, GERMANY; DIETER HELDMANN, BERLIN, GERMANY; CHRISTOPH-STEPHAN HILGER, BERLIN, GERMANY; LUDGER DINKELBORG, BERLIN, GERMANY;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/EP98/05741 09/10/1998

METHOD FOR TREATING PROLIFERAITYE DISEASES BY THERAPY

Foreign Applications

GERMANY 197 42 680.0 09/23/1997 GERMANY 197 41 695.0 09/18/1997 GERMANY 197 41 694.2 09/18/1997

If Required, Foreign Filing License Granted 06/07/2000

**aliiT** 

Preliminary Class

**†09** 

Date: 06/07/2000

Team: OIPE

Pata entry by: BARRETO, NGA

#### 1881 BER KIND HOR KIND HOR BER KIND HOR HOR KIND

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

## <u>GRANTED</u>

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CRF 5.15(a) unless an earlier license has been issued under 37 CRR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CRR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (S2 CFR 121-128)); the Office of Department of State (with respect to Arms, Munitions and Implements of War (S2 CFR 121-128)); the Office of Department of State (with respect to Arms, Munitions and Implements of War (S2 CFR 121-128)); the Office of Department of State (with respect to Arms, Munitions and Implements of War (S2 CFR 121-128)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 from the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

#### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

  The words "new," "improved " "improved as first words in the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the
  Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along
  with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

MA 82:9 00/r/8

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231